Colchicine’s Second Act: A Meta-Analysis Confirms Its Role in Coronary Artery Disease
A systematic review and meta-analysis of 20 randomized trials, encompassing over 21,000 patients with coronary artery disease (CAD), has found that colchicine significantly reduces major adverse cardiovascular events (MACE) without increasing serious adverse events. The analysis, published in Clinical Pharmacology & Therapeutics, showed a 30% reduction in MACE and also found reductions in myocardial infarction and revascularization procedures. Importantly, the benefit was consistent regardless of whether patients presented with acute coronary syndromes or chronic coronary syndrome, though the drug did increase the risk of gastrointestinal side effects.
Why it might matter to you:
This meta-analysis provides high-level evidence that can directly inform your prescribing decisions for a common, low-cost anti-inflammatory drug in cardiology. It clarifies a clinical controversy by showing that colchicine’s benefit in CAD is not limited to a specific patient presentation, which simplifies treatment algorithms. For your training in evidence-based medicine, it’s a practical example of how meta-analyses resolve uncertainties from individual trials with seemingly conflicting results.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
